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Caloric restriction of db/db mice
reverts hepatic steatosis and body
weight with divergent hepatic
metabolism
Kyung Eun Kim1,*, Youngae Jung2,*, Soonki Min2,3,*, Miso Nam2,3, Rok Won Heo1,
Byeong Tak Jeon4, Dae Hyun Song5, Chin-ok Yi1, Eun Ae Jeong1, Hwajin Kim1,
Jeonghyun Kim6, Seon-Yong Jeong6, Woori Kwak7, Do Hyun Ryu3, Tamas L. Horvath8,
Gu Seob Roh1,8 & Geum-Sook Hwang2,9
Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent causes of liver disease and its
prevalence is a serious and growing clinical problem. Caloric restriction (CR) is commonly recommended
for improvement of obesity-related diseases such as NAFLD. However, the effects of CR on hepatic
metabolism remain unknown. We investigated the effects of CR on metabolic dysfunction in the liver
of obese diabetic db/db mice. We found that CR of db/db mice reverted insulin resistance, hepatic
steatosis, body weight and adiposity to those of db/m mice. 1H-NMR- and UPLC-QTOF-MS-based
metabolite profiling data showed significant metabolic alterations related to lipogenesis, ketogenesis,
and inflammation in db/db mice. Moreover, western blot analysis showed that lipogenesis pathway
enzymes in the liver of db/db mice were reduced by CR. In addition, CR reversed ketogenesis pathway
enzymes and the enhanced autophagy, mitochondrial biogenesis, collagen deposition and endoplasmic
reticulum stress in db/db mice. In particular, hepatic inflammation-related proteins including lipocalin-2
in db/db mice were attenuated by CR. Hepatic metabolomic studies yielded multiple pathological
mechanisms of NAFLD. Also, these findings showed that CR has a therapeutic effect by attenuating the
deleterious effects of obesity and diabetes-induced multiple complications.
Over the past decade, the prevalence of diabetes has dramatically increased across all genders and age groups
and has reached epidemic proportions in developed and developing countries due to increased obesity rates1.
In particular, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are features
of metabolic syndrome and are strongly associated with insulin resistance, dyslipidemia, obesity, and hyperglycemia leading to type 2 diabetes (T2D)2,3. In NAFLD, glycerolipids accumulate in the liver (causing hepatic
steatosis) due to an imbalance between lipid storage and lipid removal2. Also, NAFLD disturbs hepatic lipid and
glucose metabolism and causes inflammation in the liver4. NASH, a severe form of NAFLD that is accompanied
by inflammation and fibrosis, progresses to cirrhosis and hepatic failure5. Thus, various pathological changes in
genes and proteins, including those that produce metabolites, contribute to the progression of NAFLD.
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Figure 1. Effects of caloric restriction (CR) on obesity and hepatic steatosis in db/db mice. Food intake
(A) and body weight (B) of db/db and db/m mice. Gross morphology (C) and weight (D) of intraabdominal
fat deposits (epididymal fat pads, mesentery fat, and perirenal fat) and the liver. (E) Histological analysis of
hepatic fat accumulation by H&E and Oil red O staining. Scale bar, 100 μm. (F) NAFLD activity score and
concentration of hepatic triglycerides (TGs). Data are shown as the mean ±  SEM. *p < 0.05 for db/db versus
db/m mice. †p < 0.05 for db/db+CR versus db/db mice.

Caloric restriction (CR) reduces mortality in diverse species from age and other causes, including diabetes,
cancer, cardiovascular disease, and brain atrophy6,7. The effects of CR on lifespan and health span have been
known for nearly a century. Generally, CR causes major metabolic reprogramming toward efficient fuel utilization
and a reduction in oxidative damage to macromolecules8. Although a range of putative mechanisms have been
proposed, the precise molecular mechanisms underlying these effects remain unknown9.
Previous studies have shown that NAFLD changes the levels of metabolites, proteins and genes in the liver
of human5,10,11 and animal models3,6. In particular, NAFLD causes the accumulation of lipids in the liver and
results in inflammation and mitochondrial dysfunction12,13. It has also been reported that CR alters metabolism;
however, these findings have been limited to normal mouse models and confirmed its effect against aging and/or
dietary excess14,15. Moreover, the process of improvement from NAFLD caused by CR treatment is unclear. In this
study, we examined alterations in hepatic metabolism caused by CR treatment in the context of NAFLD of db/db
mice, to investigate several metabolic pathways related to CR and NAFLD. We also investigated the hypothesis
that long-term CR administration protects against NAFLD by inhibiting hepatic steatosis, autophagy, endoplasmic reticulum (ER) stress, mitochondrial fission, inflammation, and collagen deposition.

Results

Effects of CR on metabolic parameters and hepatic steatosis in db/db mice.

To investigate the
effect of CR on obesity and diabetes-induced metabolic disturbances in db/db mice, mice were maintained on the
normal standard diet chow (ND) or CR (2 g/day) for 12 weeks (Fig. 1A). The total caloric intake of db/db mice was
85.09 ± 0.86% higher than db/m mice and 123.53 ± 16.47% higher than db/db+CR mice (P < 0.0001) (Fig. S1).
Two weeks after CR, the body weight of db/db+CR mice was reduced compared with db/db mice (Fig. 1B). The
size and weight of intraabdominal fat deposits and livers of db/db mice decreased after CR (Fig. 1C,D). H&E and
Oil Red O staining showed that hepatic steatosis in db/db mice was reduced by CR administration (Fig. 1E). The
analysis of histological scoring for NAFLD activity revealed that the liver histology in db/db mice was significantly improved by CR (Fig. 1F). Consistent with the Oil Red O staining, we found that the hepatic triglyceride
(TG) concentration, which is higher in db/db mice, was significantly decreased by CR (Fig. 1F). To determine the
Scientific Reports | 6:30111 | DOI: 10.1038/srep30111
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db/m (n = 10)

db/db (n = 10)

db/db+CR (n = 10)

Insulin (ng/mL)

Metabolic parameters

0.98 ±  0.22

5.43 ±  1.94*

1.17 ±  0.24†

Leptin (ng/mL)

15.22 ±  1.79

41.09 ±  4.08*

26.60 ±  2.92†

8107.44 ±  848.93

7685.24 ±  669.70

9925.84 ±  414.03†

77.20 ±  8.15

248.89 ±  48.60*

120.80 ±  16.01†

Adiponectin (μg/mL)
AST (U/L)
ALT (U/Ll)

29.00 ±  1.62

234.00 ±  54.77*

66.40 ±  11.14†

396.50 ±  30.68

864.00 ±  87.52*

851.10 ±  69.01

Total cholesterol (mg/dL)

93.00 ±  7.48

214.67 ±  18.05*

98.40 ±  7.82†

Triglyceride (mg/dL)

70.60 ±  7.76

163.89 ±  11.71*

123.10 ±  13.34†

Free fatty acid (μEq/L)

1100.00 ±  101.85

1930.89 ±  206.23*

1839.50 ±  152.69

Glucose (mg/dL)

Table 1. Serum metabolic parameters in db/db mice with or without CR. Data are presented as the
mean ±  SEM. *P < 0.05 for db/db mice vs. db/m mice, †P < 0.05 for db/db+CR vs. db/db mice. AST, aspartate
aminotransferase; ALT, alanine aminotransferase; CR, caloric restriction.

effects of CR on serum metabolic parameters in db/db mice with or without CR, we measured the concentration
of various proteins. As shown in Table 1, hyperinsulinemia, hyperleptinemia, and hypoadiponectinemia in db/db
mice were reversed by CR. We also found that hepatic enzymes and total cholesterol were higher in db/db mice
than in db/m mice, and were significantly decreased by CR. However, serum glucose, TG, and free fatty acids
(FFA) levels in db/db mice were not significantly reduced by CR (Table 1). In particular, the fasting blood glucose
levels in db/db mice were not significantly corrected by CR (Fig. S2A). To examine the effect of CR on insulin
resistance in db/db mice, we performed an insulin tolerance test (Fig. S2B). Consistent with the effects of CR on
serum insulin, the uncontrolled glucose level in db/db mice was reduced by CR (Fig. S2C).

Metabolomic profiling of the mouse liver using 1H NMR.

To investigate aqueous metabolite changes
in the liver of db/db mice with or without CR, we performed metabolic profiling using 1H nuclear magnetic
resonance (1H NMR). Representative one-dimensional 1H NMR spectra of aqueous liver samples from three
different groups are shown in Fig. S3. We quantified 40 metabolites (Table S2) and employed multivariate statistical analysis to compare mouse groups using the partial least squares discriminant analysis (PLS-DA) model
derived from the quantification. The PLS-DA score plot (Fig. 2A) showed a remarkable separation of the groups
with high goodness of fit and predictability, as indicated by the R2 and Q2 values, respectively (R2Y =  0.986,
Q2 = 0.993). Permutation tests (Fig. S4) were performed to validate PLS-DA models and the results strongly confirmed the validity of the models. Acetate, acetone, ascorbate, β-hydroxybutyrate, dimethylamine, glutathione,
and lactate separated db/db mice from other groups in loading plots and had high variable importance of projection (VIP) values (VIP > 1) (Fig. 2B,C). Among these metabolites, acetate, acetone, β-hydroxybutyrate, and
lactate are related to energy and lipid metabolism16,17, and glutathione and ascorbate are known antioxidants in
hepatic inflammation18. Quantifications and p values of these metabolites are shown in Fig. 2D,E. Ascorbate and
β-hydroxybutyrate were significantly (p < 0.017) increased in db/db mice compared to db/m mice and decreased
in db/db+CR mice. Acetone, acetate, lactate, and glutathione were significantly higher in the db/db mice compared with db/m mice, but the reduction caused by CR was not significant.

Lipidomic profiling of mouse livers using UPLC-QTOF-MS. To find lipid species related to
inflammation, energy, and lipid metabolism, we applied lipidomic profiling using ultra performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-QTOF-MS). Representative
UPLC-QTOF-MS spectra of positive and negative ionization modes obtained from db/m liver tissue are shown
in Fig. S5. We applied multivariate statistical analysis using PLS-DA models derived from positive and negative ionization modes, respectively. Each PLS-DA score plot (Fig. 3A,B) showed a clear differentiation in three
groups (R2Y =  0.986, Q2Y = 0.993 for positive ionization mode and R2Y =  0.992, Q2Y = 0.949 for negative ionization mode), and permutation tests validated the reliability of the model (Fig. S6). We identified 138 significant
(p <  0.017, VIP > 1) lipid species (119 in positive and 19 in negative ionization modes) that have different intensities in db/db versus db/db+CR as shown in heatmaps. Most glycerolipids [diacylglycerol (DG) and TG] were
higher in db/db mice than db/m mice and were decreased by CR. Some glycerolipids, such as TG and DG with
longer acyl chains (carbon numbers ≥5 8 and ≥40, respectively), were not different between db/m and db/db mice
(Fig. 3C). Glycerolphospholipids [lysophosphatidylcholine (lysoPC), lysophosphatidylethanolamine (lysoPE),
phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG),
phosphatidylinositol (PI), and phosphatidylserine (PS)] and sphingolipids [ceramide (Cer) and sphingomyelin
(SM)] mostly decreased in db/db mice compared with the db/m mice, except PE (40:6). Glycerolphospholipid
and sphingolipid levels in the db/db+CR model were mostly increased compared to the db/db model (Fig. 3D).
Effects of CR on TG synthesis and lipogenesis in the livers of db/db mice. Lipid accumulation can
increase as a result of increased fat synthesis, reduced fat oxidation, increased delivery of FFA from peripheral
adipose tissues to the liver, or enhanced de novo lipogenesis in the liver itself19. Sirtuin 1 (SIRT1), which is activated in fasted state, phosphorylates AMPK and enhances energy metabolism. We found that decreased hepatic
SIRT1 expression in db/db mice was reversed by CR, which increased AMPK activity (Fig. 4A).
The synthesis of TG in the liver is nutritionally regulated by key metabolic enzymes19. As shown in Fig. 1F and
Table S2, we found excessive accumulation of serum and hepatic TG in db/db mice. Western blotting showed that
Scientific Reports | 6:30111 | DOI: 10.1038/srep30111
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Figure 2. Quantification of aqueous metabolites in liver samples. Score scatter plot (A), variable importance of
projection (VIP) score plot (B), and loading plot (C) of the partial least-squares discriminant analysis (PLS-DA)
model. Score plot shows a good separation among db/m (circle), db/db (black dots), and db/db+caloric restriction
(CR; gray dots) mice. Identified metabolites that have high VIP values (>1) are presented in the loading plot.
Quantified metabolites (D,E) with high VIP values are related to inflammation, energy, and lipid metabolism. Data
are shown as the mean ± SEM. *p < 0.017 for db/db versus db/m mice. †p < 0.017 for db/db+CR versus db/db mice.

lipogenic proteins [acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), stearoyl-coenzyme A desaturase 1
(SCD1), and diacylglycerol acyltransferase 1 (DGAT1)], which are the key regulators of lipid synthesis in db/db
mice, were increased compared to db/m mice. However, these were significantly reversed by CR (Fig. 4B). In
particular, these lipogenic enzymes are transcriptionally regulated by sterol regulatory element-binding protein
1 (SREBP-1), carbohydrate response element binding protein (ChREBP), and liver X receptor (LXR) in the liver.
We found that CR inhibits hepatic LXRβand SREBP-1 expression in db/db mice, while increased ChREBP in
the liver of db/db mice was not reversed by CR (Fig. 4C). In particular, it is important to remove the excessive
Scientific Reports | 6:30111 | DOI: 10.1038/srep30111
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Figure 3. Alteration in lipid species due to caloric restriction (CR) in db/db mice. Partial least-squares
discriminant analysis score plots based on the UPLC-QTOF-MS-positive (A) and -negative (B) ionization
mode, from liver samples from db/m (circle), db/db (black dots), and db/db+CR (gray dots) mice. Heatmap
shows significant (p < 0.017, variable importance of projection >1) glycerolipid (C) and phospholipid and
sphingolipid (D) species altered in db/db+CR versus db/db mice. Each value in the heatmap is a colored
representation of a calculated Z-score.

accumulation of hepatic TG through autophagy. We performed western blots for light chain 3 beta (LC3B) and
p62 in the livers of db/db mice (Fig. 4D). The hepatic LC3B level was significantly reduced in db/db mice, and
a significant increase in db/db+CR mice was observed. In contrast, the increased p62 expression level in db/db
mice was significantly decreased by CR. These data indicate that hepatic steatosis-induced defective autophagy
is improved by CR.

Effects of CR on ketogenesis and mitochondrial biogenesis in the livers of db/db mice.

To
determine the effects of CR on mitochondrial β-oxidation and ketogenesis, we examined the expression of peroxisome proliferator-activated receptor α (PPARα), sirtuin 3 (SIRT3), 3-hydroxy-3-methylglutaryl CoA synthase 2

Scientific Reports | 6:30111 | DOI: 10.1038/srep30111
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Figure 4. Effects of caloric restriction (CR) on triglyceride synthesis-related lipogenesis and autophagy
in the livers of db/db mice. Western blots and quantifications showing expression levels of hepatic SIRT1 and
p-AMPK/AMPK (A), p-ACC/ACC, FAS, SCD1, and DGAT1 (B), LXR β, SREBP-1, and ChREBP (C), and
autophagy-related LC3B and P62 (D). Band intensity was normalized to β-actin, p84, or VDAC1. Data are
shown as the mean ±  SEM. *p < 0.05 for db/db versus db/m mice. †p < 0.05 for db/db+CR versus db/db mice.

(HMGCS2), and 3-hydroxybutyrate dehydrogenase, type 1 (BDH1) in mitochondria from these mice (Fig. 5A).
PPARαis the master regulator of fatty acid β-oxidation and ketogenesis20, while SIRT3 deacetylates and activates
mitochondrial HMGCS2, promoting ketogenesis in the fasted state21. We showed that PPARαand SIRT3 expression were significantly increased and decreased, respectively, in db/db mice compared to db/m mice. However,
CR did not change their expressions. In particular, only the HMGCS2 level was significantly increased in db/db
mice compared to db/m mice, while its expression in mitochondria was reduced by CR. Unlike HMGCS2, the
increased BDH1 level in db/db mice was not reduced by CR. Finally, we determined the effect of CR in db/db
mice on hepatic Slc16a6 (Fig. 5B), which acts as a ketone body transporter in the liver during fasting22. We
showed that induction of Slc16a6 in db/db mice was inhibited by CR.
Mitochondrial dysfunction contributes to the pathogenesis of NAFLD since it affects hepatic lipid homeostasis and promotes reactive oxygen species (ROS) production and lipid peroxidation, cytokine release, and
cell death23. To evaluate the effect of CR on mitochondrial biogenesis, we examined the expression of mitochondrial fission- and fusion-related proteins [dynamin-related protein 1 (Drp1) and optic atrophy 1 (autosomal
dominant) (OPA1)] and a mitochondrial carrier protein [uncoupling protein 2 (UCP2)] (Fig. 5C–E). Drp1 and
Scientific Reports | 6:30111 | DOI: 10.1038/srep30111
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Figure 5. Effects of caloric restriction (CR) on ketogenesis and mitochondrial dysfunction in the livers of db/
db mice. (A) Western blots and quantification showing ketogenesis-related mitochondrial enzymes PPARα, SIRT3,
HMGCS2, and BDH1. (B) Western blots and quantification showing hepatic Slc16a6 expression. (C) Western blots
and quantification showing hepatic mitochondrial Drp1 and UCP2 expression, with band intensity normalized
to VDAC1. (D) Immunohistochemistry detecting Drp1 in liver sections. Scale bar, 100 μm. (E) Western blots and
quantification showing hepatic mitochondrial OPA1 expression. Data are shown as the mean ±  SEM. *p <  0.05 for
db/db versus db/m mice. †p < 0.05 for db/db+CR versus db/db mice.

UCP2 expression was higher in db/db mice than in db/m mice, while their levels were decreased by CR (Fig. 5C).
Immunohistochemical staining showed that CR attenuates the increase of Drp1-positive hepatocytes in the liver
of db/db mice (Fig. 5D). In addition, we found that mitochondrial fusion-related protein OPA1 was significantly
decreased by CR (Fig. 5E).

Effects of CR on inflammation, collagen deposition, and ER stress in the livers of db/db mice.

As shown in Fig. 3, we found that CR reverses inflammation-related metabolites in db/db mice. To identify
molecules responsible for obesity/diabetes-induced inflammation, we conducted next generation sequencing
(NGS)-based RNA-seq analysis and examined hepatic gene expression profiles in db/m and db/db mice with
or without CR (Fig. 6A). We identified 44 differentially expressed genes (DEGs) (p < 0.01), listed in Table S3.
In particular, we found one gene, lipocalin-2 (LCN2), which regulates intracellular lipid droplet formation in
the liver and is closely associated with inflammation during NAFLD24. We further examined LCN2 mRNA
and protein expression in the liver, and found it was increased in db/db mice and reduced by CR (Fig. 6B,C).
Immunofluorescence staining showed that CR attenuates the increase of LCN2-positive hepatic stellate cells in
the liver of db/db mice (Fig. 6D). We found that CR attenuated increased serum LCN2 levels in db/db mice
(Fig. 6E). In support of the anti-inflammatory effect of CR, we confirmed that CR inhibited the nuclear translocation of nuclear factor-kappa B (NF-κb) p65 (Fig. S7). Western blot analysis showed that an increase in n uclear
NF-κb p65 expression in db/db mice is also decreased by CR (Fig. 6F).
Furthermore, to investigate whether CR affects hepatic collagen deposition in db/db mice with hepatic inflammation, we examined connective tissue growth factor (CTGF), collagen content, and alpha-smooth muscle actin
(α-SMA) (Fig. S8A–C). Western blot analysis showed that hepatic CTGF expression was significantly higher in
db/db mice than db/m mice, whereas its levels were significantly decreased by CR (Fig. S8A). Using the Sircol
collagen assay, we found that CR counteracted the increase in hepatic collagen in db/db mice (Fig. S8B). Finally,
immunohistochemistry showed that immunoreactivity of α-SMA-positive cells in the liver of db/db mice was

Scientific Reports | 6:30111 | DOI: 10.1038/srep30111

7

www.nature.com/scientificreports/

Figure 6. Effects of caloric restriction (CR) on inflammation in the livers of db/db mice. (A) The differential
expression of genes in WT or db/db+CR versus db/db mice was color-shaded after NGS-based RNA-seq analysis.
Genes shown in red have up-regulated expression and those shown in yellow have down-regulated expression
(Table S3). (B) Quantitative RT-PCR analysis of LCN2 in the liver. (C) Western blots and quantifications showing
hepatic LCN2 expression (band intensity normalized to β-actin). (D) Representative immunofluorescent images
of LCN2 in liver sections (scale bar, 100 μm). (E) Serum LCN2 levels. (F) Western blots and quantifications
showing nuclear NF-kBp65 expression (band intensity normalized to p84). Data are shown as the mean ±  SEM.
*p < 0.05 for db/db versus db/m mice. †p < 0.05 for db/db+CR versus db/db mice.
decreased by CR (Fig. S8C). These findings indicate that CR may inhibit the development of hepatic steatosis into
hepatic profibrotic state.
Hepatic TG can increase the accumulation of unfolded proteins in the ER, which leads to ER stress in many
metabolic diseases, including obesity, T2D, and NAFLD25. We finally examined the effects of CR on the protein
levels of some ER stress markers in the liver of db/db mice (Fig. S8D). These markers [protein kinase RNA-like
endoplasmic reticulum kinase (PERK), phospho-elF2α (p-elF2α), activating transcription factor 4 (ATF4), and
Scientific Reports | 6:30111 | DOI: 10.1038/srep30111
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CCAAT-enhancer-binding protein homologous protein (CHOP)] were significantly increased in db/db mice compared to db/m mice. Long-term CR administration significantly inhibited the increase in these ER stress markers.

Discussion

We demonstrate here that CR is a beneficial therapy to attenuate the deleterious actions of NAFLD including
lipogenesis, ketogenesis, autophagy, mitochondrial biogenesis, inflammation, collagen deposition, and ER stress
in db/db mice. In mice with an obese phenotype with fully developed T2D, we generated metabolite profiles of
NAFLD and identified several metabolites that indicate lipogenesis, ketogenesis, and inflammation reversed by
CR. Our findings support that the metabolic pathways leading to the development of hepatic steatosis are multiple and include enhanced non-esterified fatty acid release from adipose tissue (lipolysis), increased de novo fatty
acids (lipogenesis), decreased β-oxidation and mitochondrial fission in the liver. Our findings were consistent
with previous results from humans10,11,26 and we focused on the effects of CR in NAFLD for these metabolic
changes.
NAFLD is characterized by lipogenesis, disruption of autophagy, and accumulating glycerolipids in the liver
with obesity and diabetes27,28. Consistent with previous evidence that increased SIRT1 expression represses
SREBP-1 and inhibits lipid synthesis and fat storage29, hepatic SIRT1 expression was significantly decreased in db/db
mice compared to db/m mice. Likewise, our results showed that CR inhibits expression of the proteins related to
lipogenesis (FAS, SCD1, LXR β, SREBP-1, and DGAT1) and energy metabolism (phosphorylation of AMPK and
ACC) by increasing SIRT1. These data indicate that CR inhibits the accumulation of glycerolipids in the liver of
db/db mice and that they are decomposed to FFAs by enhancing autophagy. Autophagy has been identified to
regulate intracellular lipid stores through degradation of lipid droplets and release of FFA as a rapid response to
starvation30. Chronic high-fat diet (HFD) feeding of mice, which induces insulin resistance and hepatic steatosis,
impairs lipid autophagy and expression of several autophagy proteins in the liver31. Autophagy-related proteins
are decreased in the liver of ob/ob mice32. Like those of ob/ob mice, we showed that hepatic LC3B expression levels were decreased in db/db mice, but the p62 level, which is related to the inhibition of autophagy was increased
in db/db mice. These altered genes may cause an increase in ER stress, similar to that of autophagy deficiency in
db/db mice. In contrast, levels of hepatic LC3B and p62 expressions are reversed by CR.
SREBP-1, ChREBP, and LXR in the liver are associated with transcriptional regulation of TG synthesis19.
SREBP-1 and ChREBP are required for transcriptional control by insulin and glucose, respectively33. These two
transcriptional factors efficiently respond to carbohydrates. However, we found that hepatic ChREBP expression
in db/db mice was not reversed by long-term CR. The activation of ChREBP regulated by glucose contributes to
translocation from the cytosol into the nucleus34. We found that nuclear ChREBP localization in the liver of db/db
mice was increased compared to that in db/m mice. However, its expression was not inhibited by CR. Thus, we
hypothesize that ChREBP may play an important role in hepatic lipogenesis in NAFLD. In support of this, db/db
mice are characterized by severe hyperglycemia with loss of beta cells35. For the reason that CR did not reduce
serum FFA levels in db/db mice, the clearance from increased lipolysis in adipose tissues and released FFA into
circulation may be not completely done by CR for 12 weeks. These data indicate that the induction of lipogenic
genes is under the control of SREBP-1 and ChREBP in response to insulin and glucose, respectively. However,
glucose-dependent ChREBP is not controlled by CR.
PPARαis mainly present in the liver and regulates the expression of genes that encode for enzymes involved
in fatty acid transport, lipid binding and activation, and peroxisomal and mitochondrial fatty acid β-oxidation36.
PPARαactivation also stimulates de novo hepatic lipogenesis37. PPARα increases β-oxidation and gluconeogenesis during fasting4. In accordance with our results, PPARαmRNA levels are increased in streptozotocin-induced
rat liver, ob/ob, and db/db mice38,39. However, we found that increased nuclear PPARαlevels in the livers of db/db
were not inhibited by CR. As shown in Table 1, circulating FFA levels in db/db mice were not decreased by
long-term CR. We suggest that increased serum FFA from lipolysis of adipose tissues in db/db+CR mice may
play an important role in the transcriptional activity of PPARαin the liver. In addition, these data indicate that
glycerolipids are decomposed to FFAs and immediately oxidized or exported to the systemic circulation as an
energy source during CR.
SIRT3 is localized in mitochondria and plays an important role in mitochondrial metabolism40. SIRT3
is increased during fasting, including CR, and decreased in obese mice41. We also found that mitochondrial
SIRT3 expression was significantly reduced in the liver of db/db mice compared to that of db/m mice. However,
hepatic SIRT3 expression in db/db mice could be not reversed by CR. Although CR significantly decreases
β-hydroxybutylate in the liver of db/db mice, it could not attenuate the increased serum FFA and cholesterol levels of db/db mice. These data indicate that entry of excessive circulating FFAs into mitochondria in the liver can
contribute to the reduction of mitochondrial SIRT3 levels in both db/db and db/db+CR mice.
HMGCS2 is activated by mitochondrial deacetylase SIRT342. FFA oxidation is the major fuel for ketone bodies
(e.g., acetoacetate, acetone, and β-hydroxybutyrate) which are mainly used under conditions of prolonged fasting,
illness, or increased physical activity43. Obesity induces unusual lipid oxidation and ketone body production44.
Consistently, like the levels of metabolites (acetone and β-hydroxybutyrate), the level of mitochondrial HMGCS2
was increased in db/db mice, while it was significantly decreased by CR. However, the mitochondrial BDH1
level in db/db mice was augmented by CR. By contrast, interconversion of acetoacetate and β-hydroxybutyrate
by BDH1 appears to be readily reversible. BDH1, which contains several SIRT3-regulated acetylation sites, is not
affected by SIRT3, and its mitochondrial level in db/db mice cannot be changed by CR. Therefore, we expected
that many ketone bodies from fatty livers were produced for energy sources. However, these mice could not use
glucose as energy because of insulin resistance and increasing gluconeogenesis.
Slc16a6 is known as a selective β-hydroxybutyrate transporter required in the liver during fasting, that causes
impairment of hepatic ketone body secretion22. We suggest that the accumulation of ketone bodies within the
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fatty liver of db/db mice leads to an increase in Slc16a6 levels within the liver as a mechanism for adaptation to
this increased secretion of ketone bodies.
In addition to ketogenesis from β-oxidation in mitochondria, abnormality of mitochondrial dynamics is associated with enhanced fission in the liver of db/db mice. Consistently, we found that mitochondrial fission-related
enzyme Drp1 was increased in the liver of db/db mice and reduced by CR. This suggests that mitochondrial
fission induced by hepatic damage is reversed by CR. Expression of fusion-related protein OPA1 also increased
in db/db mice, likely to maintain mitochondrial homeostasis. UCP2 was also up-regulated in the liver of db/db
mice, which is a potential regulator of mitochondrial ROS production28,45. Our results indicate that CR partially
attenuates obesity-induced mitochondrial fragmentation and ROS production.
In db/db mice, long-chain fatty acids (LCFAs) are oxidized in peroxisomes and the ER in place of mitochondria, because of carnitine palmitoyltransferase 1 (CPT1) inhibition43. This increased FFA oxidation in the ER
causes ER stress46. ER stress is evident in the liver of obese mice and plays a critical role in the development of
insulin resistance and diabetes47. We found that enzymes related to ER stress, such as PEPK, P-elF2a, ATF, and
CHOP, were activated in db/db+CR mice. We hypothesized that ROS induced by NAFLD contribute to lipotoxicity in hepatocytes. Levels of glutathione and ascorbate antioxidants were increased in db/db mice. These results
suggest that CR reduces the load for protein folding in the ER in db/db mice, and thus reduces the activity of
PERK followed by regulation of the elF2α-ATF4 axis in the liver. As a result, ROS from ER stress is reduced and
major lipids in the membrane (PC, PE, and SM) are restored. Improvement of the lipid membrane may protect
mitochondria from lipotoxicity and increase fat metabolism, by reducing glycerolipids in hepatocytes.
In addition to examining autophagy and ER stress in the liver of db/db mice, we confirmed the beneficial effect
of CR on inflammation. Obesity and T2D are closely associated with chronic inflammation characterized by an
abnormal cytokine production and the activation of a network of inflammatory signaling pathways48. We found
that glycerolphospholipids and sphingolipids in db/db mice are significantly decreased by CR. Among these
lipids, PC, PE, and SM are known to have a major role in hepatic cell membranes27,46,49. Kidd et al.49 have shown
that ROS inactivates the membrane proteins that depend on the lipids for activity and weakens the membrane
to the point of rupture. Other research has reported that inflammatory mediators activate SM-synthase and that
SM-synthase makes SM and DG from ceramide and PC50. SM then accumulates in the outer membrane, and DG
activates protein kinase C (PKC) and NF-κB, which are transcription factors of inflammation50. From our study,
low levels of lipids (phospholipids and sphingolipids) and high levels of LCN2 and NF-κB (Fig. 7A–E) showed
that the lipid membrane was decomposed and inflammatory response occurred in db/db mice. LCN2 is closely
associated with obesity and T2D in humans51, and its gene expression is up-regulated in adipose tissue and the
liver of genetically obese animals52. LCN2 induction is activated by the pro-inflammatory cytokine IL-1β, which
is induced by the NF-κB pathway53. Consistently, we found that LCN2 and nuclear NF-κB p65 protein levels
were increased in db/db mice compared to db/m mice, but reduced by CR. We also found that increased levels of
CTGF and α-SMA expression in db/db mice were attenuated by long-term CR. Therefore, our findings indicate
that obesity and diabetes-induced hepatic inflammation can be suppressed by CR, preventing the hepatic fibrosis
that can occur as a result of chronic inflammation.
In conclusion, the present study explored the therapeutic effects of CR on NAFLD in db/db mice. We found
that CR reduces obesity by suppressing the lipogenesis pathway in the liver of db/db mice. CR also improved
hepatic steatosis, inflammation, and ER stress, and partially modulated mitochondrial dynamics. These results
are summarized in Fig. 7, and suggest that CR may have beneficial effects on metabolic disorders. Our findings
provide potential biomarkers for the multiple risk assessment of NAFLD and further insight into therapeutic
strategy for NAFLD development.

Methods

Animals and the caloric restriction model.

Five-week-old male db/db and db/m mice from the
C57BL/6J background were purchased from Central Lab Animal, Inc. (Seoul, South Korea) and maintained in the
animal facility at Gyeongsang National University. Experiments were performed in accordance with the National
Institutes of Health Guidelines on the Use of Laboratory Animals (GNU-130306-M0021). All experimental protocols were approved by the ethics committee of Gyeongsang National University. Mice were individually housed
with an alternating 12-h light/dark cycle. Starting at five weeks of age, mice were fed a normal standard diet chow
(ND) for five weeks. Mice were then randomly divided into three groups, db/m, db/db and db/db+CR (n =  10
per group), at 10 weeks of age. For the db/db+CR group, db/db mice were transferred to individual cage and
received a restricted amount of food (2 g/day) for 12 weeks as previously described44. The db/m and db/db mice
were given free access to food. Mice were weighed four times monthly and immediately prior to their sacrifice at
22 weeks of age.

Tissue collection and sample preparation. For histological evaluation, the mice (n = 3 per group) were
anesthetized with zoletil (5 mg/kg, Virbac Laboratories, Carros, France) and transcardially perfused with heparinized saline and 4% paraformaldehyde. Six hours after fixing, the liver was processed for paraffin embedding
and sectioned (5 μm). Liver sections were stained with hematoxylin and eosin (H&E) and visualized under a
BX51 light microscope (Olympus, Tokyo, Japan). The histological analysis from three H&E stained liver sections
each mice (n = 3 per group) was performed using the histological scoring system for NAFLD activity by an experienced pathologist without prior knowledge of the groups. The NAFLD activity score was quantified by summing
the scores of steatosis (0–3), lobular inflammation (0–2), and hepatocellular ballooning (0–2).
Hepatic TG colorimetric assay.

Frozen livers were homogenized and centrifuged, and the supernatants
were used to determine triglyceride (TG) levels. TG concentrations (n = 7 per group) were measured by a TG
colorimetric assay kit (Cayman Chemical Company, Ann Arbor, MI, USA).
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Figure 7. Changes in hepatocyte metabolism in non-alcoholic fatty liver disease (NAFLD) and caloric
restriction (CR) states. Increased metabolites and enzymes are shown in red and decreased in blue. Nondetection or no change is shown in black. (A) NAFLD model compared with the db/m model. (B) CR model
compared with the NAFLD model.

Oil Red O staining. To determine hepatic lipid accumulation, frozen liver sections (5 μm) were stained with
0.5% Oil Red O (Sigma–Aldrich, St. Louis, MO, USA) for 10 min, washed, and counterstained with Mayer’s hematoxylin (Sigma–Aldrich) for 45 sec. The sections were visualized under a BX51 light microscope (Olympus).
Measurement of serum metabolic parameters. For serum analysis, the mice (n = 10 per group) were
intramuscularly anesthetized with zoletil. Serum glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), free fatty acids (FFA), total cholesterol, and triglyceride (TG) levels were determined at the Green
Cross Reference Laboratory (Young, South Korea). Serum adiponectin, leptin, insulin, and lipocalin-2 (LCN2)
were measured using mouse adiponectin, leptin, insulin (Shibayagi Co., Gunma, Japan), and LCN2 (R&D
Systems, MN, USA) enzyme-linked immunosorbent assay (ELISA) kits.
Metabolic profiling of liver tissue based on 1H-NMR and UPLC-QTOF-MS. For metabolite profiling of lipids and aqueous metabolites in liver tissue (n = 7 per group), ultra-performance liquid chromatography (UPLC) (Waters, Maidstone, UK) coupled to the quadrupole time of flight mass spectrometry (QTOF-MS)
(ESI/Triple TOF 5600; SCIEX, Concord, ON, Canada) and 1H-nuclear magnetic resonance (1H-NMR) (Agilent
Technologies Inc. Santa Clara, CA, USA) were used, respectively. For further details, see Supplementary data.
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Tissue fractionation and western blot analysis. For protein extraction (n = 7 per group), frozen liver
tissue was homogenized in lysis buffer (15 mM HEPES [pH 7.9], 0.25 M sucrose, 60 mM KCl, 10 mM NaCl, 1 mM
ethylene glycol tetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, and 2 mM NaF). Homogenized tissues were
incubated on ice for 20 min and sonicated. Samples were then centrifuged for 20 min at 12,000 rpm at 4 °C and
supernatants were transferred to clean vials. For cytosolic and nuclear fraction preparations, livers were chopped
in ice-cold lysis buffer (10 mM HEPES-KOH [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, protease inhibitors), homogenized, and centrifuged for 1 min at 12,000 rpm. The supernatant was collected as a cytosol fraction and a nuclear
pellet was resuspended in high-salt extraction buffer (20 mM HEPES-KOH [pH 7.9], 1.5 mM MgCl2, 420 mM
NaCl, 0.2 mM EDTA, 25% glycerol, protease inhibitors, 0.5 mM DTT) and incubated on ice for 20 min, then centrifuged for 10 min at 12,000 rpm. The supernatant was collected as a nuclear fraction and centrifuged sequentially
as described by Andrews and Faller54. For the separation of cytosolic and mitochondrial fractions, we used a mitochondrial isolation kit (Bio-Rad, Hercules, CA, USA). Samples were probed with primary antibodies (Table S1)
and protein bands were detected using enhanced chemiluminescence substrates (Pierce, Rockford, IL, USA). The
Multi-Gauge image analysis program (version 3.0; Fujifilm, Tokyo, Japan) was used for densitometry analysis.
Immunohistochemistry. Deparaffinized sections of liver were placed in 0.3% H2O2 for 10 minutes, washed,

and incubated in blocking serum for 20 min. Sections were incubated in primary antibodies (Table S1) at 4 °C
overnight and with a secondary biotinylated antibody for 1 h at room temperature. After washing, sections were
incubated in an avidin-biotin-peroxidase complex solution (Vector Laboratories, Burlingame, CA, USA) and
developed with 0.05% diaminobenzidine (Sigma-Aldrich) containing 0.05% H2O2. The sections were then dehydrated in graded alcohols, cleared in xylene, and mounted under a coverslip with Permount (Sigma-Aldrich).
Sections were visualized under a BX51 light microscope (Olympus).

Next generation sequencing (NGS)-based RNA-seq analysis. C&K genomics (Seoul, South Korea)
performed preparation of an RNA-seq library, sequencing, and bioinformatics analysis. Briefly, sequencing was
performed by Illumina HiSeq2000 and the quality-filtered reads were aligned to the Mus_musculus genome
(GRCm38) from the Ensembl database. The R package DESeq55 was used to find DEGs (p < 0.01), which were
then converted to official gene symbols and grouped by a common biological property according to Gene
Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. The enriched GO
terms were used to functionally cluster DEGs, which were then filtered (p < 0.05). The RNA sequencing data from
this study have been deposited under the NCBI Project Accession Number: PRJNA305333.
Quantitative real-time reverse-transcription PCR (qRT-PCR). Total RNAs were isolated using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and reverse-transcribed using the RevertAid  First-Strand
cDNA Synthesis Kit (Fermentas, Inc., Hanover, MD, USA). Real-time RT-PCR was performed using the
ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). PCR amplifications were performed using the SYBR Green I qPCR kit (TaKaRa, Shiga, Japan) with specific primers:
5′-CCCCATCTCTGCTCACTGTC-3′and 5′-TTTTTCTGGACCGCATTG-3′ for mouse LCN2 (GenBank:
NM_008491), and 5′- TGACCACAGTCCATGCCATC-3′and 5′-GACGGACACATTGGGGGTAG-3′for mouse
Gapdh (GenBank: NM_001289726).

™

Statistical analysis. A multivariate statistical analysis was performed using SIMCA-P+software (version
12.0, Umeå, Sweden). Partial least-squares discriminant analysis (PLS-DA) was conducted for model discrimination. Score plots, loading plots, and variable importance of projection (VIP) values were obtained from the
PLS-DA model. For further details, see Supplementary data.
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